【摘要】 目的探讨早期胃癌患者内镜黏膜剥离术(ESD)术后1年血清胃蛋白酶原比值(PGR)、胃泌素-17 (G-17)、糖类抗原-125(CA125)水平变化及预后情况,为患者的诊断提供指导。方法回顾性分析2014年1月至2018年12月本院接收诊治的80例早期胃癌ESD手术患者的诊疗资料,将其设为研究组,并选取同期50例健康者为对照组。对比患者术前、术后1年及对照组血清PGR、G-17、CA125的检测水平,并对其进行预后评估。结果术后1年,患者的血清PGR水平(9.57±1.23)明显高于术前(3.29±0.64),血清G-17、CA125水平[(9.03±1.66)pmol/L、(20.05±3.36)U/ml]均明显低于术前[(22.31±3.07)pmol/L、(87.07±10.29)U/ml],差异均有统计学意义(P<0.05);术后1年,患者血清PGR、G-17、CA125水平与对照组相比,差异无统计学意义(P>0.05);患者术后1年复发率、生存率分别为0.00%、100.00%。结论ESD术治疗早期胃癌患者的效果满意,有效调节患者血清胃蛋白酶原、胃泌素、糖类抗原水平,且促进患者预后恢复,值得推广应用。更多还原

【Abstract】 Objective To investigate the changes and clinical significance of serum pepsinogen ratio(PGR), gastrin-17(G-17) and carbohydrate antigen-125(CA125) in patients with early gastric cancer one year after endoscopic mucosal dissection(ESD). Methods 80 cases of early gastric cancer treated with ESD surgery werereceived inour hospital from January 2016 to December 2018, andretrospective analyzed, and set it as the study group. 50 healthy people in the same period wereselected as the control group. The levels of serum PGR, G-17 and CA125 in the control group were compared before and 1 year after operation, and the prognosis was evaluated. Results One year after surgery, the serum PGR level(9.57±1.23) was significantly higher than that before surgery(3.29±0.64), and the serum G-17 and CA125 levels [(9.03±1.66) pmol/L,(20.05±3.36)U/mL] were significantly lower than that before surgery [(22.31±3.07) pmol/L,(87.07±10.29)U/mL], the difference were statistically significant(P<0.05).1 year after surgery,the serum PGR, G-17, CA125 levels of the patients compared with those of the control group, the differences were not statistically significant(P>0.05). The 1-year recurrence rate and survival rate of patients were 0.00% and 100.00%, respectively. Conclusion ESD is effective in the treatment of patients with early gastric cancer, effectively regulating the levels of serum pepsinogen, gastrin and carbohydrate antigens in patients, which is worthy of popularization and application.更多还原